Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 5/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7282918 | 1.00 | ALDH1A1 (0.71) | ALDH1A1GLAADRA2CTDP1DRD4 | |
| SCHEMBL93244 | 1.00 | ALDH1A1 (0.71) | ALDH1A1GLAADRA2CTDP1DRD4 | |
| SCHEMBL29769262 | 1.00 | ALDH1A1 (0.71) | ALDH1A1GLAADRA2CTDP1DRD4 | |
| SCHEMBL679937 | 0.90 | ALDH1A1 (0.78) | ALDH1A1GLAADRA2CTDP1DRD4 | |
| SCHEMBL22357196 | 0.90 | ALDH1A1 (0.78) | ALDH1A1GLAADRA2CTDP1DRD4 | |
| SCHEMBL28424897 | 0.89 | ALDH1A1 (0.71) | ALDH1A1GLAADRA2CTDP1DRD4 | |
| SCHEMBL29929987 | 0.89 | ALDH1A1 (0.57) | ALDH1A1GLAADRA2CTDP1DRD4 | |
| SCHEMBL12590671 | 0.88 | ALDH1A1 (0.65) | ALDH1A1GLAADRA2CTDP1DRD4 | |
| SCHEMBL17432746 | 0.87 | ADRA2C (0.62) | ALDH1A1GLAADRA2CTDP1DRD4 | |
| SCHEMBL11053460 | 0.86 | ADRA2C (0.60) | ALDH1A1GLAADRA2CTDP1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155697-A1 | SUBSTITUTED PIPERAZINES | Auspex Pharmaceuticals Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7498338-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-03-03 | — | — | US | disclosed |
| WO-2008157240-A1 | SUBSTITUTED PIPERAZINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20070129393-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| EP-1687311-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049620-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | WO | disclosed |
| CN-1315830-A | Method for treating anxiety disorders | LILLY CO ELI (US) | 2001-10-03 | — | — | CN | disclosed |
| US-6242450-B1 | SUBSTITUTED PIPERIDINES | ELI LILLY AND COMPANY | 2001-06-05 | — | — | US | disclosed |
| WO-2000006082-A2 | TREATMENT OF ANXIETY DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006166-A1 | 5-HT1F ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976746-A1 | 5-HT1F antagonists | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| EP-0976747-A2 | Use of 5HT-1F receptor antagonists for treating anxiety disorders | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| US-4567264-A | ADRENERGIC BLOCKING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1986-01-28 | — | — | US | disclosed |
| EP-0126449-A1 | Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry | SYNTEX (U.S.A.) INC. (US) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129393-A1 | Novel compounds | C1R, CHRM1, CHRM2 | ALDH1A1 2759/4885GLA 3557/4885ADRA2C 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.